Kadcyla Trastuzumab Emtansine for Injection Package Insert (赫赛莱)

Chinese package insert for Kadcyla (trastuzumab emtansine) 100 mg and 160 mg for injection: indications, dosing, dose adjustment tables and warnings.


Kadcyla Trastuzumab Emtansine for Injection Package Insert (赫赛莱) - cover page
Brand
赫赛莱
Category
Drugs
Document type
User Manual
Language
Chinese
Pages
24
File format
PDF
File size
1.6 MB
Published
10 November, 2026
Updated
10 November, 2026
MD5 checksum
14BFFB1583D42C70301689C95D6730DC

About this manual

This is the Chinese package insert for Kadcyla (赫赛莱), trastuzumab emtansine for injection, a HER2-targeted antibody-drug conjugate supplied as a white to off-white sterile lyophilized powder for intravenous infusion in 100 mg and 160 mg vials. It states the drug name, active ingredient and excipients, molecular weight, description, indications in early and metastatic HER2-positive breast cancer, and the available strengths.

The document sets out the recommended dose of 3.6 mg/kg every three weeks, the 90-minute first infusion with observation for at least 90 minutes and the possible 30-minute later infusions, treatment duration for early and advanced breast cancer, dose-reduction levels and dose-adjustment tables for liver enzyme, bilirubin, platelet, left ventricular and pulmonary events, dosing in special populations, and instructions for reconstitution, handling and disposal. This manual is written in Chinese.

What's inside

  • Warnings
  • Drug Name
  • Ingredients
  • Description
  • Indications
  • Specifications
  • Dosage and Administration
  • Dose Adjustments
  • Dosing in Special Populations
  • Special Instructions for Use, Handling and Disposal

Specifications

Strengths100 mg/vial; 160 mg/vial
Active ingredientTrastuzumab emtansine, a HER2-targeted antibody-drug conjugate (ADC)
Molecular weightApproximately 148,781 Da
ExcipientsSuccinic acid, sodium hydroxide, polysorbate 20, sucrose
Dosage formWhite to off-white sterile lyophilized powder for intravenous infusion
Recommended dose3.6 mg/kg by intravenous infusion once every 3 weeks (21-day cycle)
Reconstitution volume5 mL sterile water for injection for the 100 mg vial; 8 mL for the 160 mg vial

Frequently asked questions

What is the recommended dose of Kadcyla?

The recommended dose is 3.6 mg/kg given by intravenous infusion once every 3 weeks, with a 21-day cycle.

What vial strengths are available?

The product is supplied in 100 mg/vial and 160 mg/vial strengths.

Can Kadcyla be given as a rapid injection?

No. It must be given as an intravenous infusion and must not be given as an intravenous push or rapid intravenous injection.

How long is the first infusion?

The starting dose is given as a 90-minute intravenous infusion, with observation during the infusion and for at least 90 minutes afterwards.

Download PDF (1.6 MB)